A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Metabolism And Disposition

• Publication date

  2016-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.116.070391PMID 27260151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data

  2016cited by this paper
• Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group

  2015influential reference
• Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery.

  2015cited by this paper
• Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

  2013cited by this paper
• Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy

  2013cited by this paper
• N-Acetylation of Etamicastat, a Reversible Dopamine-β-Hydroxylase Inhibitor

  2013cited by this paper
• A Perspective on the Contribution of Metabolites to Drug-Drug Interaction Potential: The Need to Consider Both Circulating Levels and Inhibition Potency

  2013cited by this paper
• Which Metabolites Circulate?

  2013cited by this paper
• Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State

  2013cited by this paper
• The early estimation of circulating drug metabolites in humans

  2012cited by this paper
• Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters

  2010cited by this paper
• Metabolites: have we MIST out the importance of structure and physicochemistry?

  2010cited by this paper
• Predicting circulating human metabolites: how good are we?

  2009cited by this paper
• Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

  2009cited by this paper
• Qualitative Analysis of the Role of Metabolites in Inhibitory Drug‐Drug Interactions: literature evaluation based on the Metabolism and Transport Drug Interaction Database

  2009cited by this paper
• From known knowns to known unknowns: predicting in vivo drug metabolites.

  2009cited by this paper
• Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.

  2009cited by this paper
• Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition

  2009cited by this paper
• Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug

  2008cited by this paper
• Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species

  2007cited by this paper
• INTERSPECIES DIFFERENCES IN PHARMACOKINETICS AND METABOLISM OF S-3-(4-ACETYLAMINO-PHENOXY)-2-HYDROXY-2-METHYL-N-(4-NITRO-3-TRIFLUOROMETHYLPHENYL)-PROPIONAMIDE: THE ROLE OF N-ACETYLTRANSFERASE

  2006cited by this paper
• Role of pharmacologically active metabolites in drug discovery and development.

  2006cited by this paper
• A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery.

  2005cited by this paper
• Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.

  2004cited by this paper
• Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes

  2004cited by this paper
• Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.

  2004cited by this paper
• Issues Related to the Use of Canines in Toxicologic Pathology—Issues With Pharmacokinetics and Metabolism

  2003cited by this paper
• Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.

  2003cited by this paper
• Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes

  2003cited by this paper
• Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations

  1999cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

  1996cited by this paper
• Classification of benzodiazepine hypnotics in humans based on receptor occupancy theory

  1993cited by this paper
• Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents.

  1990cited by this paper
• Pharmacologically Active Drug Metabolites: Therapeutic and Toxic Activities, Plasma and Urine Data in Man, Accumulation in Renal Failure

  1976cited by this paper

• Identification, structural elucidation and nonclinical characterization of oxMET1: A further major metabolite of xevinapant?

  2026cites this paper
• Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development

  2020cites this paper